Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies
Friday, April 19, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix has reported initial findings from a Phase 1a/b trial of NX-5948, a selective Bruton’s tyrosine kinase degrader. This trial targets patients with relapsed or refractory B-cell malignancies, showcasing a novel therapeutic approach. The company aims to leverage these findings to enhance treatment options for cancer and autoimmune diseases.
Price reaction · baseline $14.44 (2024-04-18 close) · hit pre-market · clean, no other NRIX news in the window
day 0 close
-5.9%
day 1 · peak
-6%
day 3
-4.8%
Market Sentiment Analysis
POSITIVE FACTORS
Initial findings indicate potential efficacy of NX-5948.
The trial focuses on a novel approach to treating B-cell malignancies.
Nurix is advancing its portfolio to address significant medical needs.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-5948?
NX-5948 is a selective Bruton’s tyrosine kinase degrader developed by Nurix.
What type of patients are involved in the trial?
The trial involves patients with relapsed or refractory B-cell malignancies.
What phase is the NX-5948 trial currently in?
The NX-5948 trial is currently in Phase 1a/b.
What is the goal of the NX-5948 trial?
The trial aims to evaluate the efficacy of NX-5948 in treating B-cell malignancies.